End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
46.03 CNY | -1.29% | +4.76% | +14.96% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The company is in a robust financial situation considering its net cash and margin position.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- The firm trades with high earnings multiples: 26.12 times its 2024 earnings per share.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is not the most generous with respect to shareholders' compensation.
- Revenue estimates are regularly revised downwards for the current and coming years.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+14.96% | 6.44B | C | ||
-34.16% | 14.83B | B- | ||
-24.55% | 12.04B | B | ||
-25.24% | 6.52B | B | ||
-8.01% | 6.15B | C+ | ||
-2.34% | 4.64B | D- | ||
+60.00% | 4.62B | C | ||
-8.10% | 3.93B | B | ||
-11.16% | 3.49B | C- | ||
-6.77% | 3.05B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 603939 Stock
- Ratings Yifeng Pharmacy Chain Co., Ltd.